Skip to main content
Top
Gepubliceerd in: Tijdschrift voor Gerontologie en Geriatrie 3/2006

01-06-2006 | Klinische les

Rivastigmine als ondersteuning bij het dilemma van de behandeling van hallucinaties optredend bij ziekte van Parkinson

Auteurs: J. M. P. Rovers, Dr. P. L. J. Dautzenberg, J. P. ter Bruggen

Gepubliceerd in: Tijdschrift voor Gerontologie en Geriatrie | Uitgave 3/2006

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Abstract

We report three cases of patients with Parkinson’s disease without dementia, admitted to our hospital because of hallucinations. The anti-Parkinson medication was adapted and the patients started with rivastigmine. As a result, hallucinations no longer occurred. A 79 years old man also required short-term quetiapine because of agitation and anti-Parkinson doses were without side effects, as a result of which mobility improved. An 84 years old woman reported mild side effects of rivastigmine, without consequences, whereas her mobility appeared to be good. A 72 years old woman reported mild memory problems upon admission, which improved during admission, as did her mobility after increasing the anti-Parkinson medication doses. Treatment of rivastigmine can be useful in the therapeutic dilemma in the treatment of hallucinations in patients with Parkinson’s disease (start anti-psychotic or reduce anti-Parkinson medication). In addition to adapting anti-Parkinson doses and sometimes short-term treating with an anti-psychotic, treatment with rivastigmine appears to be a quick improvement, without serious side effects. Also, mobility can improve, due to the possibility of increasing the anti-Parkinson doses, if necessary. Because of the many remaining questions, prospective randomised trials are needed.
Literatuur
go back to reference Schrag A, Ben-Shlomo Y, Quinn N. How common are complications of Parkinson’s disease? J Neurol 2002;249:419-23.CrossRefPubMed Schrag A, Ben-Shlomo Y, Quinn N. How common are complications of Parkinson’s disease? J Neurol 2002;249:419-23.CrossRefPubMed
go back to reference Goetz CG, Stebbings GT. Mortality and hallucinations in nursing home patients with advanced Parkinson’s disease. Neurology 1995;45:669-71.PubMed Goetz CG, Stebbings GT. Mortality and hallucinations in nursing home patients with advanced Parkinson’s disease. Neurology 1995;45:669-71.PubMed
go back to reference Fenelon G, Mahieux F, Huon R, Ziegler M. Hallucinations in Parkinson’s disease: prevalence, phenomenollogy and risk factors. Brain 2000;123:733-45.CrossRefPubMed Fenelon G, Mahieux F, Huon R, Ziegler M. Hallucinations in Parkinson’s disease: prevalence, phenomenollogy and risk factors. Brain 2000;123:733-45.CrossRefPubMed
go back to reference Laar van T. Achtergrond en behandeling van cognitieve stoornissen en hallucinaties bij de ziekte van Parkinson. Tijdschrift voor Neurologie en Neurochirurgie 2006;107:32-9. Laar van T. Achtergrond en behandeling van cognitieve stoornissen en hallucinaties bij de ziekte van Parkinson. Tijdschrift voor Neurologie en Neurochirurgie 2006;107:32-9.
go back to reference Lemstra AW, Eikelenboom P, Gool v WA. Cholinerg deficiëntie syndroom als een indicator voor cholinesterase remmers. Ned Tijdschr Geneeskd 2003;147:2201-3.PubMed Lemstra AW, Eikelenboom P, Gool v WA. Cholinerg deficiëntie syndroom als een indicator voor cholinesterase remmers. Ned Tijdschr Geneeskd 2003;147:2201-3.PubMed
go back to reference McKeith I, Del Ser T, Spano P-F et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double blind, placebo-controlled international study. Lancet 2000;356:2031-6.CrossRefPubMed McKeith I, Del Ser T, Spano P-F et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double blind, placebo-controlled international study. Lancet 2000;356:2031-6.CrossRefPubMed
go back to reference Emre M, Aarsland d, Albanese A et al. Rivastigmine for dementia associated with parkinson’s disease. N Eng J Med 2004;351:2509-18.CrossRef Emre M, Aarsland d, Albanese A et al. Rivastigmine for dementia associated with parkinson’s disease. N Eng J Med 2004;351:2509-18.CrossRef
go back to reference Fernandez HH, Trieschmann ME, Friedman JH. Treatment of psychosis in Parkinson’s disease. Safety considerations. Drug safety 2003;26(9):643-659.CrossRefPubMed Fernandez HH, Trieschmann ME, Friedman JH. Treatment of psychosis in Parkinson’s disease. Safety considerations. Drug safety 2003;26(9):643-659.CrossRefPubMed
go back to reference Finkel SF. Pharmacology of antipsychotics in the elderly: a focus on atypicals. J Am Geriatr Soc 2004;52:S258-S265.CrossRefPubMed Finkel SF. Pharmacology of antipsychotics in the elderly: a focus on atypicals. J Am Geriatr Soc 2004;52:S258-S265.CrossRefPubMed
go back to reference Bullock R, Cameron A. Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson’s disease: A case series. Current medical research and opinion 2002;18:258-264.CrossRefPubMed Bullock R, Cameron A. Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson’s disease: A case series. Current medical research and opinion 2002;18:258-264.CrossRefPubMed
go back to reference Reading PJ, Luce AK, McKeith IG. Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial. Movement Disorders 2001;16:1171-4.CrossRefPubMed Reading PJ, Luce AK, McKeith IG. Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial. Movement Disorders 2001;16:1171-4.CrossRefPubMed
Metagegevens
Titel
Rivastigmine als ondersteuning bij het dilemma van de behandeling van hallucinaties optredend bij ziekte van Parkinson
Auteurs
J. M. P. Rovers
Dr. P. L. J. Dautzenberg
J. P. ter Bruggen
Publicatiedatum
01-06-2006
Uitgeverij
Bohn Stafleu van Loghum
Gepubliceerd in
Tijdschrift voor Gerontologie en Geriatrie / Uitgave 3/2006
Print ISSN: 0167-9228
Elektronisch ISSN: 1875-6832
DOI
https://doi.org/10.1007/BF03074779

Andere artikelen Uitgave 3/2006

Tijdschrift voor Gerontologie en Geriatrie 3/2006 Naar de uitgave

Proefschrift in discussie

Epidemiology of late life depression

Signalementen

Signalementen